The MOMENTUM study is a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anaemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and secondary endpoints, achieving statistically significant benefit on symptoms, anaemia and splenic size.
Professor Claire Harrison, Guy’s & St Thomas’ Hospital, London said: this is great news, a positive trial which should help make an important drug available for patients.
You can read the full press release here.
